S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Did You See These Trend Reversals? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Did You See These Trend Reversals? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Did You See These Trend Reversals? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Did You See These Trend Reversals? (Ad)pixel
UK travelers face hours-long waits for ferries to France
Small areas reopen near Fukushima nuclear plant, few return
Did You See These Trend Reversals? (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
Did You See These Trend Reversals? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
NASDAQ:CYTK

Cytokinetics - CYTK Stock Forecast, Price & News

$35.19
+0.98 (+2.86%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$34.70
$36.66
50-Day Range
$33.36
$45.71
52-Week Range
$32.96
$55.80
Volume
3.04 million shs
Average Volume
1.15 million shs
Market Capitalization
$3.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.21

Cytokinetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
62.6% Upside
$57.21 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
-0.17mentions of Cytokinetics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$3 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.41) to ($4.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

201st out of 996 stocks

Pharmaceutical Preparations Industry

84th out of 484 stocks


CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Mizuho Securities Sticks to Their Buy Rating for Cytokinetics (CYTK)
Mizuho Securities Keeps Their Buy Rating on Cytokinetics (CYTK)
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
3/01/2023
Today
4/01/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
253
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$57.21
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+64.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-410.89%
Pretax Margin
-411.21%

Debt

Sales & Book Value

Annual Sales
$94.59 million
Book Value
($1.14) per share

Miscellaneous

Free Float
90,810,000
Market Cap
$3.36 billion
Optionable
Optionable
Beta
0.85

Social Links


Key Executives

  • Robert I. BlumRobert I. Blum
    President, Chief Executive Officer & Director
  • Eric Terhaerdt
    Vice President-Development Operations
  • Ching W. JawChing W. Jaw
    Chief Financial Officer & Senior Vice President
  • Fady Ibraham MalikFady Ibraham Malik
    Executive Vice President-Research & Development
  • Andy Wolff
    Senior VP-Clinical Research & Development













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2023?

12 Wall Street research analysts have issued 1-year target prices for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they predict the company's stock price to reach $57.21 in the next twelve months. This suggests a possible upside of 62.6% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 on January 1st, 2023. Since then, CYTK shares have decreased by 23.2% and is now trading at $35.19.
View the best growth stocks for 2023 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Wednesday, March, 1st. The biopharmaceutical company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by $0.23. The biopharmaceutical company had revenue of $1.96 million for the quarter, compared to analysts' expectations of $7.10 million. Cytokinetics had a negative trailing twelve-month return on equity of 1,401.63% and a negative net margin of 410.89%. The firm's quarterly revenue was down 96.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.36) earnings per share.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.00 million-$5.00 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $35.19.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.36 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($4.25) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 253 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 4/2/2023 by MarketBeat.com Staff